Dermatology
| Atopic Dermatitis
Dermatology
Atopic Dermatitis
Efficacy and safety of lebrikizumab is maintained up to 3 years in patients with moderate-to-severe atopic dermatitis: ADvocate 1 and ADvocate 2 to ADjoin long-term extension trial
book_2
Source:
EADV 2024 - Oral session
calendar_today
Published on Medfyle:
October 2024
import_contacts
6
min
In this medfyle
A late-breaking abstract from EADV 2024 explores the efficacy and safety of lebrikizumab up to 3 years in patients with atopic dermatitis, showing most responders maintain clear or almost clear skin with continuous treatment.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
©2024 Infomedica-Medfyle. All rights reserved.
Source: Efficacy and safety of lebrikizumab is maintained up to 3 years in patients with moderate-to-severe atopic dermatitis: ADvocate 1 and ADvocate 2 to ADjoin long-term extension trial. Thaçi D, et al. Presented at EADV 2024; Abstract #7829.
The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.
